Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04283019 · ClinicalTrials.gov registry record · Phase 1
The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT04283019: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT04283019 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04283019, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacokinetic and pharmacodynamic effects of oral Cannabidiol (with or without low levels of THC), under acute and chronic dosing conditions.
Interventions
- DRUG THC
- DRUG CBD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2021-08-15 |
| Est. Completion | 2024-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04283019
The ClinicalTrials.gov registry entry for NCT04283019 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which THC is the first listed.
NCT04283019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04283019 about?
NCT04283019 is a clinical study titled "The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions". This study will evaluate the pharmacokinetic and pharmacodynamic effects of oral Cannabidiol (with or without low levels of THC), under acute and chronic dosing conditions.
What is the current status of trial NCT04283019?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2021-08-15. Estimated completion is 2024-06-17.
What interventions are being tested in trial NCT04283019?
The interventions under investigation include: THC (DRUG), CBD (DRUG).
Who is sponsoring clinical trial NCT04283019?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.